"Pharmaceutical Speed ​​Reading Society" Zhong Suisui resigns from the post of chairman of the subsidiary of Yangshengtang

[March 23, 2021 / List of medical information] Zhong Sui Sui retires from the post of chairman of the subsidiary of Yangshengtang; AstraZeneca announces the latest phase 3 clinical results of the new crown vaccine.

[March 23, 2021 / List of medical information] Daily fresh medicines and medical news, Speed ​​Reading Club will pay attention to you together!

Part1 Policy Brief

Part1 policy briefing Part1 policy briefing

The Ministry of Education Announces the Revocation of Rural Medicine Specialty

The Ministry of Education Announces the Revocation of Rural Medicine Specialty

On March 22, the Ministry of Education of the People's Republic of China issued the "Notice on Printing and Distributing the "Catalogue of Vocational Education (2021)".

National Health Commission: Nucleic acid testing and vaccination information will be integrated into the health code

National Health Commission: Nucleic acid testing and vaccination information will be integrated into the health code

Mao Qun'an, director of the Planning Department of the National Health Commission, said at a press conference of the National Health Commission on the 23rd that the country has basically achieved "one code access".

Medical Insurance Bureau: Adhere to the "Internet + Medical Services" reasonable price comparison between online and offline

Medical Insurance Bureau: Adhere to the "Internet + Medical Services" reasonable price comparison between online and offline

On March 23, Xiong Xianjun, director of the Medical Service Management Department of the Medical Insurance Bureau, said that at present, all provinces and cities across the country have introduced "Internet +" medical service prices and medical insurance payment policies.

The State Food and Drug Administration revises the instructions for systemic fluoroquinolones

The State Food and Drug Administration revises the instructions for systemic fluoroquinolones

On March 23, the State Food and Drug Administration issued the "Announcement on Revising the Instructions for Use of Fluoroquinolones for Systemic Use (No.

Part2 Observation

Part2 Sankei Observation Part2 Sankei Observation

Zhong Suansui resigns from the post of chairman of the subsidiary of Yangshengtang

Zhong Suansui resigns from the post of chairman of the subsidiary of Yangshengtang

According to an enterprise investigation, Youdao Biopharmaceutical (Hangzhou) Co.

Xiao Guoliang, independent director of Zhenbaodao Pharmaceutical, resigns

Xiao Guoliang, independent director of Zhenbaodao Pharmaceutical, resigns

On March 23, Zhenbaodao Pharmaceutical issued an announcement stating that the board of directors had recently received a resignation report from independent director Xiao Guoliang.

Donge Ejiao issued an announcement on the salary adjustment of the company's senior management staff

Donge Ejiao issued an announcement on the salary adjustment of the company's senior management staff

On March 20, Donge Ejiao issued an announcement and held the nineteenth meeting of the Ninth Board of Directors.

A wholly-owned subsidiary of Tus Pharmaceuticals obtained the "Drug Production License"

A wholly-owned subsidiary of Tus Pharmaceuticals obtained the "Drug Production License"

On March 23, TusHoldings issued an announcement stating that its wholly-owned subsidiary, Chinese Medicine Company, had recently obtained the "Drug Production License" issued by the Hunan Provincial Drug Administration.

Zhongyin Technology completes 70 million yuan of Pre-A round of financing

Zhongyin Technology completes 70 million yuan of Pre-A round of financing

Artery Network recently learned that Zhongyin Technology completed a pre-A round of financing of 70 million yuan, led by Hetang Venture Capital, and investment institutions such as Longmen Capital.

Part3 Medicine News

Part3 Medicine News Part3 Medicine News

AstraZeneca announces latest phase 3 clinical results of new crown vaccine

AstraZeneca announces latest phase 3 clinical results of new crown vaccine

Today, AstraZeneca announced that the new crown vaccine AZD1222 jointly developed by the company and the University of Oxford has obtained positive results in a phase 3 clinical trial conducted in the United States.

Roche's PD-L1 antibody Tecentriq in the Phase 3 clinical trial of NSCLC patients reached the primary endpoint

Roche's PD-L1 antibody Tecentriq in the Phase 3 clinical trial of NSCLC patients reached the primary endpoint

On March 22, Roche’s Genentech announced that its PD-L1 antibody Tecentriq has reached the primary endpoint in a phase 3 clinical trial for the treatment of patients with early-stage non-small cell lung cancer.

Roche stops antisense RNA therapy tominersen Phase III clinical study

Roche stops antisense RNA therapy tominersen Phase III clinical study

In response to Huntington's disease, Roche signed a patent license agreement with Ionis in 2017 for a new antisense therapy for proteins related to Huntington's disease.

Heboplatinum anti-tumor combination therapy completed the first patient's administration in Phase 1 clinical trial

Heboplatinum anti-tumor combination therapy completed the first patient's administration in Phase 1 clinical trial

On March 22, Harmonicare announced that its anti-CTLA-4 antibody HBM4003, an open phase 1 study for patients with advanced melanoma and other solid tumors in China, has completed the first patient medication.

The targeted anticancer drug Pepaxto is included in the NCCN clinical practice guidelines for multiple myeloma in the United States

The targeted anticancer drug Pepaxto is included in the NCCN clinical practice guidelines for multiple myeloma in the United States

Recently, Oncopeptipes AB announced that its targeted anticancer drug Pepaxto has been included in the clinical practice guidelines for multiple myeloma in the National Oncology Network.

Precision therapy for advanced gynecological cancer achieves positive results

Precision therapy for advanced gynecological cancer achieves positive results

Today, Leap Therapeutics announced that its investigational inhibitor DKN-01, which targets a new target DKK1, as a single agent or in combination with paclitaxel, has obtained positive results in a phase 2 "basket" clinical trial for the treatment of advanced gynecological cancer.

Novo Nordisk's application for high-dose semaglutide for the treatment of diabetes is rejected by the FDA

Novo Nordisk's application for high-dose semaglutide for the treatment of diabetes is rejected by the FDA

On March 22, Novo Nordisk issued an announcement stating that the company had received a notification of rejection (RFL) from the US FDA concerning the label extension application for 2.
0 mg of semaglutide once a week for the treatment of type 2 diabetes.
When the FDA determines that additional information is needed to review a complete application, it will send an RFL to the pharmaceutical company.
(Sina Pharmaceutical News)

FDA approves Merck's Keytruda for esophageal cancer and gastroesophageal junction cancer

FDA approves Merck's Keytruda for esophageal cancer and gastroesophageal junction cancer

Recently, the US FDA approved Merck’s Keytruda combined with platinum and fluoropyrimidine chemotherapy for the treatment of metastatic or locally advanced esophageal cancer and gastroesophageal junction cancer that are not suitable for surgical resection or radiotherapy and chemotherapy.
Just last week, Merck announced that the European Commission has approved the expansion of the anti-PD-1 therapy Keytruda label as a single-drug therapy for the treatment of 3 years and older, autologous stem cell transplantation failure, or at least received without ASCT Adult and pediatric patients with relapsed or refractory classic Hodgkin’s lymphoma with 2 therapies.
(Sina Pharmaceutical News)

Stryker orthopedic surgical robot approved for major indications

Stryker orthopedic surgical robot approved for major indications

On the 23rd, the reporter learned exclusively that following the domestic market for total hip replacement indications, Stryker’s orthopedic surgical robot was also approved domestically for total knee replacement indications.
Open information shows that in addition to Mako, there are currently several domestic joint surgery robots under development in China, including the Honghu orthopedic surgery navigation system of the minimally invasive medical robot, and the "Orthopedic surgery navigation positioning system of Tianzhihang.
" (Kechuangban Daily)

Hebei Renhe Yikang Pharmaceutical Sodium Valproate Injection is about to be approved

Hebei Renhe Yikang Pharmaceutical Sodium Valproate Injection is about to be approved

Recently, Hebei Renheyikang Pharmaceutical entered the administrative examination and approval stage with the imitation of 3 types of sodium valproate injection, which is expected to be approved in the near future and won the first imitation in China.
Sodium valproate is a broad-spectrum antiepileptic drug that does not contain nitrogen, and it is clinically used for various epilepsy where other antiepileptic drugs are ineffective.
(Minenet)

Ripretinib introduced by Zai Lab will be approved soon

Ripretinib introduced by Zai Lab will be approved soon Ripretinib introduced by Zai Lab will be approved soon

Recently, Zai Lab/Deciphera Pharmaceuticals’ application for import of category 5.
1 new drugs for "Ripretinib tablets" has been changed in the NMPA status to "under approval" and is expected to be formally approved in the near future.
The indications are: 3 or more types of cheeses have been accepted in the past.
Adult advanced gastrointestinal stromal tumors with amino acid kinase inhibitors.
(CPhl Pharmaceutical Online)

Jinling Pharmaceutical's ferrous succinate tablets obtained the consistency evaluation of the National Food and Drug Administration

Jinling Pharmaceutical's ferrous succinate tablets obtained the consistency evaluation of the National Food and Drug Administration

On March 23, Jinling Pharmaceutical issued an announcement stating that the branch Jinling Pharmaceutical Factory had recently received a notice of acceptance of the consistency evaluation of ferrous succinate tablets issued by the State Food and Drug Administration.
It is reported that the drug is a commonly used, safe and effective drug for the prevention and treatment of iron deficiency anemia.
(Announcement from Jinling Pharmaceutical)

Hisun Pharmaceutical: Epirubicin Hydrochloride for Injection passed the consistency evaluation of generic drugs

Hisun Pharmaceutical: Epirubicin Hydrochloride for Injection passed the consistency evaluation of generic drugs

On March 23, Hisun Pharmaceutical announced that the company's epirubicin hydrochloride for injection has passed the quality and efficacy consistency evaluation of generic drugs.
Epirubicin hydrochloride for injection is mainly suitable for the treatment of malignant lymphoma, breast cancer, lung cancer, soft tissue sarcoma, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, melanoma, colorectal cancer, ovarian cancer, multiple myeloma, and leukemia.
(Announcement from Hisun Pharmaceutical)

Huahai Pharmaceutical Sitagliptin Phosphate Tablets Received Acceptance from CDE

Huahai Pharmaceutical Sitagliptin Phosphate Tablets Received Acceptance from CDE

Today, Huahai Pharmaceutical was accepted by the CDE for its imitation of Sitagliptin phosphate tablets of the 4 types of applications.
Sitagliptin is a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor developed by Merck.
Compared with traditional hypoglycemic drugs, sitagliptin does not increase the risk of hypoglycemia and affect body weight.
Neutrality, good cardiovascular safety and other advantages.
(Minenet)